The top 20 global biopharmaceutical companies experienced mixed performances in their individual market capitalisations in the third quarter (Q3) of 2025, amid headwinds from US President Donald Trump’s tariffs and drug pricing pressures, with companies that demonstrated robust pipeline development reaping success. As a result, their combined market capitalisation rose 4% from $3.7 trillion (trn) on 30 June 2025 to $3.8trn on 30 September 2025, according to GlobalData, a leading data analytics and research ...

Core Viewpoint - Arrowhead Pharmaceuticals has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference therapeutic aimed at treating tauopathies, including Alzheimer's disease, which is a leading cause of cognitive and functional decline [1] Company Summary - Arrowhead Pharmaceuticals, Inc. is focused on developing RNAi therapeutics, with ARO-MAPT being a key investigational product targeting tauopathies [1] - The company is seeking regulatory approval to begin clinical trials, indicating progress in its research and development efforts [1] Industry Summary - Tauopathies, particularly Alzheimer's disease, represent a significant area of concern in neurodegenerative diseases, highlighting the need for innovative treatment options [1] - The announcement reflects ongoing advancements in the field of RNA interference therapies, which may offer new avenues for addressing complex neurological conditions [1]